If you have been reading about human growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Alpha decay energy follows the same trend as for other heavy elements. The lighter astatine isotopes have quite high decay energies, which become lower as more neutrons are added, reaching a minimum at 125 neutrons (astatine-210), even though 126 (astatine-211) is the magic number. The decay energies increase much more steeply, though, on the next two steps, reaching a high at 128 neutrons where the alpha-decay product would have the magic number of 126. Here this is astatine-213, releasing the highest energy and having the shortest life (125 ns) of all the isotopes. The energy then declines again, and alpha lifetimes increase quickly, no long-lived astatine isotope exists; this happens due to the increasing role of beta decay. This decay mode is especially important for astatine: as early as 1950, it was postulated that the element has no beta-stable isotopes (i.e. ones that do not undergo beta decay at all), though nuclear mass measurements reveal that 215At is in fact beta-stable, as it has the lowest mass of all isobars with A = 215. A beta decay mode has been found for all other astatine isotopes except for 212-216At and their isomers. Among other isotopes, if they do not undergo alpha decay: astatine-210 and the lighter isotopes decay by electron capture or positron emission, 211 by electron capture only, and astatine-217 and heavier isotopes undergo β- decay. Astatine-212, 214, and 216 should be able to decay either way.
Computationalism is the position in the philosophy of mind that the human mind is an information processing system and that thinking is a form of computing. Computationalism argues that the relationship between mind and body is similar or identical to the relationship between software and hardware and thus may be a solution to the mind–body problem. This philosophical position was inspired by the work of AI researchers and cognitive scientists in the 1960s and was originally proposed by philosophers Jerry Fodor and Hilary Putnam. Philosopher John Searle characterised this position as "strong AI": "The appropriately programmed computer with the right inputs and outputs would thereby have a mind in exactly the same sense human beings have minds." Searle challenges this claim with his Chinese room argument, which attempts to show that even a computer capable of perfectly simulating human behaviour would not have a mind.
== Weapons == Someone hit by a shotgun will not fly backwards like it is often portrayed in movies, and the same is true for other handheld weapons. The momentum of the bullet is no higher than the recoil transmitted to the shooter, which is too little to cause any significant motion. Land mines explode immediately when stepped on. They are not armed when stepped on and then triggered by stepping off, as depicted in fictional portrayals where disarming the mine is a source of narrative.
It had two taxiways and a 6,800-by-400-foot (2,070 by 120 m) runway. In June 1945, the 67th CB arrived to build a 35,000 man recreation center to be turned over to CBMU 608. In 1950, John C. Woods, who executed the Nazi war criminals convicted at the Nuremberg trials, died by accidental electrocution while stationed on Enewetak Atoll.
A submarine can have a variety of sensors, depending on its missions. Modern military submarines rely almost entirely on a suite of passive and active sonars to locate targets. Active sonar relies on an audible "ping" to generate echoes to reveal objects around the submarine. Active systems are rarely used, as doing so reveals the sub's presence. Passive sonar is a set of sensitive hydrophones set into the hull or trailed in a towed array, normally trailing several hundred feet behind the sub. The towed array is the mainstay of NATO submarine detection systems, as it reduces the flow noise heard by operators. Hull mounted sonar is employed in addition to the towed array, as the towed array can not work in shallow depth and during maneuvering. In addition, sonar has a blind spot "through" the submarine, so a system on both the front and back works to eliminate that problem. As the towed array trails behind and below the submarine, it also allows the submarine to have a system both above and below the thermocline at the proper depth; sound passing through the thermocline is distorted resulting in a lower detection range. Global climate change and warmer oceans may complicate detecting submarines at depth in most places in the world. Submarines also carry radar equipment to detect surface ships and aircraft. Submarine captains are more likely to use radar detection gear than active radar to detect targets, as radar can be detected far beyond its own return range, revealing the submarine. Periscopes are rarely used, except for position fixes and to verify a contact's identity.
Sources: en.wikipedia.org
Asparagine peptide lyase are one of the seven groups in which proteases, also termed proteolytic enzymes, peptidases, or proteinases, are classified according to their catalytic residue. The catalytic mechanism of the asparagine peptide lyases involves an asparagine residue acting as nucleophile to perform a nucleophilic elimination reaction, rather than hydrolysis, to catalyse the breaking of a peptide bond. The existence of this seventh catalytic type of proteases, in which the peptide bond cleavage occurs by self-processing instead of hydrolysis, was demonstrated with the discovery of the crystal structure of the self-cleaving precursor of the Tsh autotransporter from E. coli. These enzymes are synthesized as precursors or propeptides, which cleave themselves by an autoproteolytic reaction. The self-cleaving nature of asparagine peptide lyases contradicts the general definition of an enzyme given that the enzymatic activity destroys the enzyme. However, the self-processing is the action of a proteolytic enzyme, notwithstanding the enzyme is not recoverable from the reaction.
The MT-ND6 gene is located in human mitochondrial DNA from base pair 14,149 to 14,673. MT-ND6 is the only protein-coding gene located on the L-strand of the human mitogenome. The encoded protein is 18 kDa and composed of 172 amino acids. MT-ND6 is one of seven mitochondrial genes encoding subunits of the enzyme NADH dehydrogenase (ubiquinone), together with MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, and MT-ND5. Also known as Complex I, this enzyme is the largest of the respiratory complexes. The structure is L-shaped with a long, hydrophobic transmembrane domain and a hydrophilic domain for the peripheral arm that includes all the known redox centres and the NADH binding site. MT-ND6 and the rest of the mitochondrially encoded subunits are the most hydrophobic of the subunits of Complex I and form the core of the transmembrane region.
The protein content of C. vulgaris varies from 42 to 58% of its biomass dry weight. These proteins are considered as having a good nutritional quality compared to the standard profile for human nutrition of the World Health Organization and Food and Agriculture Organization, as the algae synthesizes amino acids. The algae also contains lipids (5–40% of the dry mass), carbohydrates (12–55% dry weight), and pigments including chlorophyll, reaching 1–2 % of the dry weight. Containing dietary minerals and vitamins, C. vulgaris is marketed as a dietary supplement, food additive, or food colorant. Extracted proteins have been investigated for manufacturing of emulsion and foams. It is not widely incorporated in food products due to its dark green color and smell similar to that of fish. As a dietary supplement, it may be sold as capsules, extracts, tablets or powder. Vitamin B12, specifically in the form of methylcobalamin, has been identified in Chlorella vulgaris.
The first use of radioluminescence was in luminous paint containing radium, a natural radioisotope. Beginning in 1908, luminous paint containing a mixture of radium and copper-doped zinc sulfide was used to paint watch faces and instrument dials, giving a greenish glow. Phosphors containing copper-doped zinc sulfide (ZnS:Cu) yield blue-green light; copper and manganese-doped zinc sulfide (ZnS:Cu,Mn), yielding yellow-orange light are also used. Radium-based luminescent paint is no longer used due to the radiation hazard posed to persons manufacturing the dials. These phosphors are not suitable for use in layers thicker than 25 mg/cm2, as the self-absorption of the light then becomes a problem. Zinc sulfide undergoes degradation of its crystal lattice structure, leading to gradual loss of brightness significantly faster than the depletion of radium. ZnS:Ag coated spinthariscope screens were used by Ernest Rutherford in his experiments discovering the atomic nucleus. Radium was used in luminous paint until the 1960s, when it was replaced with the other radioisotopes mentioned above due to health concerns. In addition to alpha and beta particles, radium emits penetrating gamma rays, which can pass through the metal and glass of a watch dial, and skin. A typical older radium wristwatch dial has a radioactivity of 3–10 kBq and could expose its wearer to an annual dose of 24 millisieverts if worn continuously. Another health hazard is its decay product, the radioactive gas radon, which constitutes a significant risk even at extremely low concentrations when inhaled.
He plants several bombs on Earth and challenges S.P.D.'s Earth unit to find them as part of a game he played on previous planets before he destroyed them while using his tiny size to hide. After Ban finds him disguised as a walkie-talkie, Byz Goa retaliates by piloting a Kaijuki called Cannon Gladiator 2 (キャノングラディエーター2, Kyanon Guradiētā Tsū), only to be deleted by Dekaranger Robo. Byz Goa is voiced by Tomokazu Seki (関 智一, Seki Tomokazu). Dradian Goldom (ドラド星人ゴルドム, Dorado Seijin Gorudomu): A criminal from Planet Drad who kidnaps Attika Alpachi's son to force him into taking a city block hostage while Goldom robs a nearby bank in the confusion, only for the Dekarangers to realize the truth. Goldom attempts to escape in his Kaijuki, Terrible Terror 2 (テリブルテーラー2, Teriburu Tērā Tsū), but is deleted by Deka Bike Robo. Goldom is voiced by Takaya Kuroda (黒田 崇矢, Kuroda Takaya). Amoreian Baachiyo (アモーレ星人バーチョ, Amōre Seijin Bacho): A hermaphroditic spider-themed criminal and stalker from Planet Amore who possesses four tendrils capable of firing spider silk-like threads to restrain targets and whose people earned a reputation for being overly passionate and "too in love". Following a brief encounter with Tetsu while the officer was working undercover as a woman, falling in love with "her", and eventually metamorphosing from his powerless immature form to his stronger adult form, Baachiyo stalks Swan Shiratori with the belief that she was the person he fell in love with.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.